Evidence map›Paper›PMID 38606155›Full record

ArticleFrontiers in medicine2024

Co-design of a paediatric oncology medicines database (ProCure) to support complex care provision for children with a hard-to-treat cancer.

Carolyn G Mazariego, Skye McKay, Elijah Tyedmers, Lauren Kelada, Brittany C McGill, Rebecca Daly, Claire E Wakefield, David S Ziegler, Natalie Taylor

Abstract read
In one paragraph

Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Carolyn G MazariegoSchool of Population Health, UNSW Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.
Skye McKaySchool of Population Health, UNSW Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.
Elijah TyedmersSchool of Population Health, UNSW Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.
Lauren KeladaSchool of Clinical Medicine, University of New South Wales (UNSW) Sydney, Sydney, NSW, Australia.
Brittany C McGillSchool of Clinical Medicine, University of New South Wales (UNSW) Sydney, Sydney, NSW, Australia.
Rebecca DalySchool of Clinical Medicine, University of New South Wales (UNSW) Sydney, Sydney, NSW, Australia.
Claire E WakefieldSchool of Clinical Medicine, University of New South Wales (UNSW) Sydney, Sydney, NSW, Australia.
David S ZieglerKids Cancer Centre, Sydney Children's Hospital, Sydney, NSW, Australia.
Natalie TaylorSchool of Population Health, UNSW Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Paediatric oncologists often encounter challenges when seeking compassionate access to off-label therapies for their patients. This study employed implementation science and co-design techniques to develop the ProCure medicines database, with the goal of streamlining the application process and addressing identified barriers in paediatric oncology. Methods: This study utilised an exploratory qualitative research design. Seventeen healthcare providers, including oncologists, nurse consultants, and allied health professionals, participated in semi-structured interviews guided by the Consolidated Framework for Implementation Research (CFIR) and a visual process map aid. Deductive qualitative data analysis, according to the CFIR constructs, identified key barriers and facilitators. Collaborative design sessions engaged multidisciplinary teams to develop the ProCure beta version. Results: Barriers to off-label therapy access included resource-intensive applications, time sensitive decision-making, and complex pharmaceutical information. Facilitators included Drug Access Navigators, Molecular Tumour Boards, and a multi-disciplinary approach. ProCure addressed end-user needs by centralising medicines information. Additional features suggested by healthcare providers included blood-brain-barrier penetrability data and successful application examples. Conclusion: ProCure represents a promising solution to the challenges paediatric oncologists face in accessing off-label therapies. By centralising information, it simplifies the application process, aids decision-making, and promotes a collaborative approach to patient care. The potential of the database to stream and enhance off-label therapy access underscores its relevance in improving paediatric oncology practise. Further research and implementation efforts are warranted to assess ProCure's real-world impact and refine its features based on user feedback.

Indexed as

CFIRco-designimplementation sciencenovel therapiespaediatric oncologyprecision medicine

Identifiers

PMID38606155
PMCPMC11007026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.